INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 204 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,595,648 | +61.4% | 193,940 | -3.7% | 0.02% | +61.5% |
| Q2 2023 | $2,228,148 | -2.4% | 201,460 | +21.9% | 0.01% | -18.8% |
| Q2 2022 | $2,283,000 | -14.6% | 165,310 | +0.7% | 0.02% | 0.0% |
| Q1 2022 | $2,672,000 | +0.4% | 164,210 | +0.5% | 0.02% | +6.7% |
| Q4 2021 | $2,662,000 | +8487.1% | 163,385 | +81592.5% | 0.02% | +1400.0% |
| Q4 2014 | $31,000 | -86.9% | 200 | -80.0% | 0.00% | -90.0% |
| Q3 2014 | $237,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |